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Abstract
The discovery of paclitaxel, an anticancer agent was a milestone in the path of anticancer drug discovery. After approval from
FDA taxol was widely used for cancer treatment. The taxol was isolated from the bark of fully grown taxus plants with is a fatal
source, to overcome this problem almost all the species were investigated for the taxol and taxol like molecules. Brevifoliol is one
of the many taxoid isolated from the taxus plants. The significance of brevifoliol was its source which was dried needles of plants
including the Himalayan yew tree Taxus wallichiana. Brevifoliol belongs to the large group of diterpenoid cyclodecanes, the same
group with which taxol belongs. In-vitro studies indicate that brevifoliol has significant activity against colon cancer cell line which
is slightly better than taxol. In the present article, all the updated information and its superiority over taxol will be discussed.
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Introduction
Taxoids are the large group of diterpenoid cyclodecanes. These
are isolated from the genus Taxus and are known and used as
anticancer agents. The first molecule from this group was Pa-
clitaxel which was isolated in 1969 in very low amount (0.01
% yield) from the bark of Pacific yew, Taxus brevifolia [1].
The structure and the mechanism of action were confirmed in
1970s [2–4].
Taxol was one of the first anticancer drugs approved by the
FDA to treat ovarian cancer and breast cancer [5].
Till date, More than 400 taxoids have been isolated from the
Taxus genus [6–8]. Brevifoliol is also an investigational antitu-
mor taxoid among a series of similar taxol derivatives by Balza
F. et al in 1972 [9] . The molecule gained attention as it was iso-
lated from the sustainable source, the needles of the Himalayan
pacific yew tree and showed promising activity against many cell
lines in-vitro.
Many in-vitro studies confirmed its anticancer properties
in different human cancer cells like CaCo2 in-vitro and in-
silico [10, 11]. Preliminary results clearly indicate that it could
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be the replacement of taxol as it shows significant activity
against many cell lines and there are many drawbacks related
to the isolation and toxicity of taxol.
Although preliminary studies showing promising results but
still many studies are required to reach the final conclusion.
This mini-review summarizes the preclinical data and other
published and unpublished reports and focuses on the clinical
usefulness of this new agent in the treatment of cancer.
Drug Information
Brevifoliol was discovered by Balza and his team [9] from
the needles of Taxus brevifolia (western yew) in a search for
the replacement of taxol in low toxicity and more effective-
ness. When it was isolated the structure was proposed as taxa-
4(20),1 l-dienel/,Sa,7p,9%,1 O/l, 13x-hexaol-9a, IO/l-diacetate-
7/I-benzoate ) named as brevifoliol. After two years the revised
structure was established by Georg et al. and Appendino et al. in
1993 [12–14] and they assigned its structure as 11(15/1)-abeo-
taxa-4(20), 11-diene skeleton (Figure 1). After isolation from
Taxus brevifolia, brevifoliol was isolated from other species of
Taxus as well. In India it was isolated from the needles of the
Himalayan yew Taxus wallichiana by Chattopadhyay et al in
2006 [11] .
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Isolation and solubility
Brevifoliol is an ample molecule (1.7 mg g- 1 fresh weight))
found in the needles of the Pacific yew Taxus brevifolia [15]and
can be isolated from the ethanolic extract of the needles of Taxus
brevifoliol and other Taxus species which is a non-destructive
mode of harvesting [9]. Another advantage associated with bre-
vifoliol is the solubility in aqueous solvents. Taxol is not soluble
in the water and other aqueous solvents.
Mechanism of Action
Brevifoliol exhibited anti-proliferative activity comparable with
the paclitaxel against all the cell lines used,) brevifoliol showed
significant activity against human colon cancer cell line, Caco2
which was comparatively higher than taxol [11]. Like taxol, bre-
vifoliol binds with the microtubule and inhibits its depolymerisa-
tion (figure 2 A and B) (In-silico and in-vitro) [16]. The CaCo2
cells treated with brevifoliol were observed to be undergoing
apoptosis through apoptosomes formation. Brevifoliol was ob-
served to express the annexin V marker of apoptosis with low
intensity of fluorescence, the indicator of late phase apoptosis.
The nucleic acid was also fragmented providing ladder-like pat-
tern due to the effect of brevifoliol. All the above-mentioned
signs were the clear-cut indication of apoptosis (Figure 2 C)
(unpublished data).
Figure 1 Structure of Brevifoliol
In order to compare the mechanism of action with that of pa-
clitaxel was studied and it is observed that brevifoliol exhibited
the same effect on microtubule dynamics as paclitaxel in terms
of the tubulin polymerization pattern (). Therefore, these obser-
vations confirmed that the brevifoliol causes the tubulin poly-
merization as paclitaxel but it was not confirmed whether bind-
ing of brevifoliol is exactly similar to paclitaxel (unpublished
data).
Figure 2 Probablemode of action of brevifoliol, normal tubulin
polymerization anddepolymerisation (A), The probable binding of
brevifoliol withmicrotubules (B)& the initiation of apoptosis in cancer
cells inpresence of brevifoliol (C)
Derivatives of brevifoliol
Till now several derivatives of brevifoliol were synthesized and
evaluated for the anticancer properties. [11, 17–19] Few of them
showed significantly increased cytotoxicity in different human
cancer cell lines. In-silico studies of derivatives of brevifoliol in-
dicated that the importance of benzoate and acetate groups of
brevifoliol as the removal of these groups makes brevifoliol in-
active [16].
Future Prospects
Brevifoliol and its derivates have shown promising activity in in-
vitro and in-silico studies. Some derivatives were showing bet-
ter activity than paclitaxel. Brevifoliol is isolated from the sus-
tainable source and can be semi-synthesised in the laboratory.
The detailed studies of brevifoliol and derivatives can provide
replacement of taxol.
Conclusion
Taxol is one of the best anticancer drugs till date (Slichenmyer,
WJ & Von Hoff DD. 1991) [20] but still has many side ef-
fects [21]. Brevifoliol shows almost similar or better anticancer
activity at in-vitro and its isolation is from non-fatal source and
has better aqueous solubility than taxol but still, further investi-
gation is going on. The further research on brevifoliol may lead
to the replacement of taxol which has many side-effects.
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